Fluclotizolam, initially synthesised in 1979 as a thienotriazolodiazepine derivative, remained unmarketed at the time. However, it resurfaced as a designer drug and was definitively identified for this purpose in 2017.
Fluclotizolam is a chemical compound classified as a thienotriazolodiazepine derivative. It was first synthesized in 1979 but was never marketed for medical use. It has gained attention as a designer drug in recent years.
Is Fluclotizolam legal?
The legal status of Fluclotizolam varies from country to country. In some places, it may be classified as a controlled substance due to its potential for misuse. It is crucial to check the specific regulations in your region.
What are the effects of Fluclotizolam?
Fluclotizolam is reported to have sedative and anxiolytic (anxiety-reducing) effects. However, its use may also lead to adverse effects, including amnesia and muscle relaxation.
Is Fluclotizolam safe to use?
The safety of Fluclotizolam is a subject of concern. It has yet to undergo the rigorous testing and evaluation required for pharmaceutical drugs. Its use can be associated with various risks, including potential side effects and long-term health consequences.
Can Fluclotizolam lead to addiction or dependence?
Like many substances with soothing properties, Fluclotizolam can potentially lead to dependence or addiction, especially when used regularly or in high doses. It is essential to be cautious and use it only as directed by a healthcare professional if it were to be prescribed, which is unlikely given its unmarketed status.
How is Fluclotizolam different from other benzodiazepines?
Fluclotizolam is a thienotriazolodiazepine derivative, which makes it structurally different from classic benzodiazepines. However, it acts on similar receptors in the brain, leading to comparable effects.
Where can I find more information about Fluclotizolam?
It’s essential to stay informed about the legal and health implications of using Fluclotizolam. You can consult your healthcare provider or local authorities for the most up-to-date information on its status and potential risks. Additionally, you can refer to credible sources and research studies for further details.
References
US 4155913: Thienotriazolodiazepine DerivativesThis patent, issued on 22 May 1979 and assigned to Hoffmann La Roche Inc, pertains to thienotriazolodiazepine derivatives. These compounds are of interest due to their potential applications, and this patent provides insights into their development.
Designer Benzodiazepines: An Expanding World of New Psychoactive SubstancesA 2019 study published in Neurotoxicology discusses designer benzodiazepines, a class of new psychoactive substances. This paper explores the growing world of these substances and their implications.
Designer Benzodiazepines: Another Class of New Psychoactive SubstancesIn this 2018 publication from the “Handbook of Experimental Pharmacology,” the authors delve into designer benzodiazepines as a subclass of new psychoactive substances. It offers valuable information about these compounds.
Les Designer Benzodiazepines: Qu’en Sait-on Aujourd’hui?”Les Designer Benzodiazepines: Qu’en Sait-on Aujourd’hui?” is a French article published in February 2018 in Toxicologie Analytique et Clinique. It provides insights into the state of knowledge about designer benzodiazepines.
‘New/Designer Benzodiazepines’: An Analysis of the Literature and Psychonauts’ Trip ReportsThis 2020 study in Current Neuropharmacology offers an analysis of “new/designer benzodiazepines” by examining the literature and reports from individuals who have used these substances.
The Psychonauts’ Benzodiazepines: Quantitative Structure-Activity Relationship (QSAR) AnalysisPublished in July 2021, this research in Pharmaceuticals delves into the quantitative structure-activity relationship (QSAR) analysis of benzodiazepines used by psychonauts. It also includes predictions of their biological activity.
In Silico Studies on Recreational Drugs: 3D Quantitative Structure Activity Relationship PredictionIn January 2023, a study was published in Chemical Biology & Drug Design focusing on in silico studies related to recreational drugs. This research provides insights into 3D quantitative structure-activity relationship predictions for classified and de novo designer benzodiazepines.
